Physician profile
Patrick Massa
NPI 1306289541
$336.29
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $83.73.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $112.60 | 2019-2020 | |
| Pfizer INC. | $48.67 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $48.20 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.16 | 2019 | |
| Daiichi Sankyo INC. | $17.14 | 2019 | |
| Shire North American Group INC | $14.39 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $13.54 | 2019 | |
| Amarin Pharma, INC. | $13.53 | 2019 | |
| Gilead Sciences, INC. | $13.30 | 2020 | |
| Lilly USA, LLC | $13.30 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.43 | 2019 | |
| Allergan, INC. | $11.03 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Massa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.